Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus …
KS Kaye, AF Shorr, RG Wunderink, B Du… - The Lancet Infectious …, 2023 - thelancet.com
Background An urgent need exists for antibiotics to treat infections caused by carbapenem-
resistant Acinetobacter baumannii–calcoaceticus complex (ABC). Sulbactam–durlobactam …
resistant Acinetobacter baumannii–calcoaceticus complex (ABC). Sulbactam–durlobactam …
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
JA Karlowsky, MA Hackel, SM McLeod… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat
serious Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including …
serious Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including …
[HTML][HTML] Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and …
J Liu, Y Shu, F Zhu, B Feng, Z Zhang, L Liu… - Journal of global …, 2021 - Elsevier
Objectives This study aimed to compare the efficacy and safety of combination therapy with
high-dose sulbactam or colistin with additional antibacterial agents for treating multidrug …
high-dose sulbactam or colistin with additional antibacterial agents for treating multidrug …
In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017
SM McLeod, SH Moussa, MA Hackel… - Antimicrobial Agents …, 2020 - Am Soc Microbiol
Acinetobacter baumannii-calcoaceticus complex (ABC) organisms cause severe infections
that are difficult to treat due to preexisting antibiotic resistance. Sulbactam-durlobactam …
that are difficult to treat due to preexisting antibiotic resistance. Sulbactam-durlobactam …
[HTML][HTML] Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis
H Chu, L Zhao, M Wang, Y Liu, T Gui… - Brazilian journal of …, 2013 - SciELO Brasil
BACKGROUND: A number of studies have reported on the effectiveness of sulbactam-
based therapies for Acinetobacter baumannii infection; however, there is little evidence that …
based therapies for Acinetobacter baumannii infection; however, there is little evidence that …
Combination Carbapenem‐Sulbactam Therapy for Critically Ill Patients with Multidrug‐Resistant Acinetobacter baumannii Bacteremia: Four Case Reports and an In …
NY Lee, CL Wang, YC Chuang, WL Yu… - … : The Journal of …, 2007 - Wiley Online Library
Infections caused by multidrug‐resistant Acinetobacter baumannii have become a
therapeutic challenge for clinicians worldwide. Although colistin and tigecycline have been …
therapeutic challenge for clinicians worldwide. Although colistin and tigecycline have been …
Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis
K Kengkla, K Kongpakwattana… - Journal of …, 2018 - academic.oup.com
Objectives To comprehensively compare and rank the efficacy and safety of available
treatment options for patients with MDR and XDR Acinetobacter baumannii (AB) infection …
treatment options for patients with MDR and XDR Acinetobacter baumannii (AB) infection …
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii
SH Moussa, AB Shapiro, SM McLeod… - Antimicrobial Agents …, 2023 - Am Soc Microbiol
Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe infections that are
difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) …
difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) …
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
H Seifert, C Müller, D Stefanik… - Journal of …, 2020 - academic.oup.com
Objectives To evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor
durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem …
durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem …
Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
D Petropoulou, M Siopi, S Vourli… - Frontiers in Cellular and …, 2022 - frontiersin.org
Background Acinetobacter baumannii is a leading cause of healthcare-associated infections
worldwide, due to both its persistence in the hospital setting and ability to acquire high levels …
worldwide, due to both its persistence in the hospital setting and ability to acquire high levels …
相关搜索
- sulbactam durlobactam acinetobacter baumannii
- sulbactam durlobactam global isolates
- baumannii infections xdr acinetobacter
- baumannii infections treatment options
- acinetobacter baumannii global isolates
- baumannii infections meta analysis
- sulbactam durlobactam molecular drivers
- sulbactam durlobactam national collection
- acinetobacter baumannii molecular drivers
- acinetobacter baumannii national collection
- xdr acinetobacter treatment options
- baumannii calcoaceticus treatment options